median EFS 7.6 mo vs. 36.0 mo, log-rank p = 0.0106) (Fig. 3A, B), which points to a predictive role of iASPP in patients with newly diagnosed AML that are intensively treated. Here, PPP1R13L is linked to acute myeloid leukemia.